Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Viruses could deliver HIV, malaria, rabies and cancer vaccines as pills

06.04.2005


Rabies, HIV, cancer and malaria could all be prevented with pills in the future, if a new technique using specially modified viruses to deliver vaccines is adopted, according to scientists speaking today (Tuesday, 05 April 2005) at the Society for General Microbiology’s 156th Meeting at Heriot-Watt University, Edinburgh.



"We can take a special type of virus which only infects bacteria, called a bacteriophage, and replace some of its DNA with vaccine DNA, and then use the phage to deliver vaccines in a highly efficient way," says Dr John March of the Moredun Research Institute, Penicuik, near Edinburgh.

A vaccine packaged in this way is cheap, simple to make, stable, and environmentally safe according to the researchers. Because the phage vaccine can be safely stored at room temperature as a dry powder, it should be possible to turn it into a pill form and deliver it as an oral vaccine. Since the phages can mass produce themselves the system would be very cheap, and easy to store and administer, making it ideal for use in the developing world to protect against diseases such as HIV/AIDS and malaria.


"We have already tested oral delivery of these vaccines, and the data suggest that they work," says Dr March. "We have successful test results from mice, rabbits and sheep - animals in which conventional DNA vaccines do not work - so we are confident that the technique will work for people. Bacteriophages have been used as medicines in eastern Europe since the 1930s to fight bacterial infections, so we have a long history of their safe use in humans, and of large scale manufacturing."

The phage vaccines have several advantages over traditional ’naked’ DNA vaccines - they can contain much larger sections of DNA, triggering a more effective immune response. Because the phage vaccine is protected within a virus shell it can be targeted at specific cells in the body, and the shell stops it breaking down and becoming ineffective.

The new vaccines can also be used for diseases where the vaccine material is difficult or expensive to produce using conventional approaches, such as for cancers. The doses needed are much smaller than conventional DNA vaccines, where high doses and multiple injection regimes are often needed. The large cloning capacity of phages means that several vaccines could be delivered simultaneously.

The main applications will be in producing cheap general vaccines for the developing world, and in specialist applications in the developed world in situations where conventional vaccines do not work. In developing countries a pill form of vaccine would do away with the need for scarce and expensive cold storage systems, and also will have no need for a constant supply of clean needles.

"Wildlife use is also ideal since phages are cheap and stable so we can use them in baits or with oral delivery," says Dr March. "This would be ideal for a rabies vaccine, where wildlife programmes will play a major role in disease eradication. The antibody response against the phage is a useful side effect as it gives us a simple marker to tell between vaccinated and naturally infected animals."

"The special phages we are using cannot replicate outside the laboratory, so they are environmentally safe and friendly," explains Dr John March. "The fact that we can make them with the bare minimum of laboratory equipment and expertise only adds to the potential of this exciting new technology."

Faye Jones | alfa
Further information:
http://www.sgm.ac.uk

More articles from Life Sciences:

nachricht The balancing act: An enzyme that links endocytosis to membrane recycling
07.12.2016 | National Centre for Biological Sciences

nachricht Transforming plant cells from generalists to specialists
07.12.2016 | Duke University

All articles from Life Sciences >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Significantly more productivity in USP lasers

In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.

Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...

Im Focus: Shape matters when light meets atom

Mapping the interaction of a single atom with a single photon may inform design of quantum devices

Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...

Im Focus: Novel silicon etching technique crafts 3-D gradient refractive index micro-optics

A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.

Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...

Im Focus: Quantum Particles Form Droplets

In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.

“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...

Im Focus: MADMAX: Max Planck Institute for Physics takes up axion research

The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.

The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

ICTM Conference 2017: Production technology for turbomachine manufacturing of the future

16.11.2016 | Event News

Innovation Day Laser Technology – Laser Additive Manufacturing

01.11.2016 | Event News

#IC2S2: When Social Science meets Computer Science - GESIS will host the IC2S2 conference 2017

14.10.2016 | Event News

 
Latest News

NTU scientists build new ultrasound device using 3-D printing technology

07.12.2016 | Health and Medicine

The balancing act: An enzyme that links endocytosis to membrane recycling

07.12.2016 | Life Sciences

How to turn white fat brown

07.12.2016 | Health and Medicine

VideoLinks
B2B-VideoLinks
More VideoLinks >>>